REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
1. Regeneron faces a class action lawsuit for misleading statements. 2. Allegations involve Eylea's pricing strategy using credit card fee payments. 3. DOJ filed a complaint claiming inflated Medicare reimbursements for Eylea. 4. Recent financial results showed lagging sales for Eylea products. 5. Regeneron's stock fell over 9% following poor earnings announcement.